|
JP5977837B2
(ja)
|
2011-12-21 |
2016-08-24 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
Ｂ型肝炎抗ウイルス剤
|
|
MX373711B
(es)
|
2012-08-28 |
2020-05-08 |
Janssen Sciences Ireland Uc |
Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
DK2961732T3
(en)
|
2013-02-28 |
2017-07-10 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
|
|
CN105102451B
(zh)
|
2013-04-03 |
2018-09-18 |
爱尔兰詹森科学公司 |
N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
DK2997019T3
(en)
|
2013-05-17 |
2018-12-03 |
Janssen Sciences Ireland Uc |
SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
KR102244937B1
(ko)
|
2013-07-25 |
2021-04-27 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
글리옥사미드 치환된 피롤아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
|
|
DK3060547T3
(en)
|
2013-10-23 |
2018-01-15 |
Janssen Sciences Ireland Uc |
CARBOXAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATMENT OF HEPATITS B
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
EP3102225B1
(en)
|
2014-02-05 |
2020-03-25 |
Novira Therapeutics Inc. |
Combination therapy for treatment of hbv infections
|
|
US11078193B2
(en)
|
2014-02-06 |
2021-08-03 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
PE20171330A1
(es)
|
2014-12-18 |
2017-09-13 |
Hoffmann La Roche |
Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
US9884831B2
(en)
|
2015-03-19 |
2018-02-06 |
Novira Therapeutics, Inc. |
Azocane and azonane derivatives and methods of treating hepatitis B infections
|
|
AU2016279330B2
(en)
*
|
2015-06-16 |
2020-05-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Piperidine derivative and preparation method and pharmaceutical use thereof
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
EP3331905B1
(en)
|
2015-08-06 |
2022-10-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
TW201718496A
(zh)
|
2015-09-29 |
2017-06-01 |
諾維拉治療公司 |
B型肝炎抗病毒劑之晶型
|
|
EP3355884B1
(en)
|
2015-10-01 |
2021-04-28 |
Olema Pharmaceuticals, Inc. |
TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
|
|
CA3011391C
(en)
*
|
2015-11-12 |
2021-02-09 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Acrylic acid derivative, preparation method and use in medicine thereof
|
|
DK3386500T3
(da)
|
2015-12-09 |
2022-12-12 |
Univ Illinois |
Benzothiophen-baserede selektive østrogenreceptor ned-regulatorer
|
|
MX2018007844A
(es)
|
2015-12-22 |
2019-01-21 |
Jiangsu Hengrui Medicine Co |
Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo.
|
|
DK3411034T3
(da)
|
2016-02-05 |
2021-01-11 |
Inventisbio Inc |
Selektiv østrogenreceptornedbrydere og anvendelser deraf
|
|
EP3442971B1
(en)
|
2016-04-01 |
2024-09-25 |
Recurium IP Holdings, LLC |
Estrogen receptor modulators
|
|
CN109640980A
(zh)
|
2016-04-15 |
2019-04-16 |
诺维拉治疗公司 |
包含壳体装配抑制剂的组合和方法
|
|
WO2017182493A1
(en)
|
2016-04-20 |
2017-10-26 |
Astrazeneca Ab |
Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
|
|
US11459617B2
(en)
|
2016-04-29 |
2022-10-04 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109843882A
(zh)
|
2016-06-16 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
JP7018026B2
(ja)
*
|
2016-06-16 |
2022-02-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ヘテロアリールエストロゲン受容体モジュレーター及びその使用
|
|
WO2018001232A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
JP2019520379A
(ja)
|
2016-07-01 |
2019-07-18 |
ジー１ セラピューティクス， インコーポレイテッド |
ピリミジン系の抗増殖剤
|
|
US10149839B2
(en)
|
2016-07-25 |
2018-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
AU2017349797B2
(en)
|
2016-10-24 |
2020-05-21 |
Astrazeneca Ab |
6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
EA201991622A1
(ru)
|
2017-01-06 |
2020-01-23 |
Г1 Терапьютикс, Инк. |
Комплексная терапия для лечения рака
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
UA125043C2
(uk)
*
|
2017-01-30 |
2021-12-29 |
Астразенека Аб |
Модулятори рецептора естрогену
|
|
US11311609B2
(en)
|
2017-02-08 |
2022-04-26 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
KR20190117582A
(ko)
|
2017-02-10 |
2019-10-16 |
쥐원 쎄라퓨틱스, 인크. |
벤조티오펜 에스트로겐 수용체 조정제
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
CN110536888B
(zh)
*
|
2017-06-20 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN110913861B
(zh)
|
2017-06-29 |
2024-01-09 |
G1治疗公司 |
G1t38的形态学形式及其制造方法
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
WO2019162429A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Center For Intelligent Research In Crystal Engineering, S.L. |
Cocrystals of ubiquinol and compositions comprising them
|
|
JP2021515769A
(ja)
|
2018-03-14 |
2021-06-24 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
カプシド集合調節剤の投薬レジメン
|
|
WO2019222272A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
EP3810283B1
(en)
|
2018-06-21 |
2023-06-14 |
F. Hoffmann-La Roche AG |
Solid forms of the tartrate salt of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, process for their preparation and methods of their use in treating cancers
|
|
WO2020009958A1
(en)
|
2018-07-03 |
2020-01-09 |
The Board Of Trustees Of The University Of Illinois |
Activators of the unfolded protein response
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
MX2021007687A
(es)
*
|
2018-12-24 |
2021-10-13 |
Inventisbio Co Ltd |
Sales novedosas de degradadores selectivos de receptores de estrogeno.
|
|
MA55020A
(fr)
|
2019-02-22 |
2021-12-29 |
Janssen Sciences Ireland Unlimited Co |
Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
AR119732A1
(es)
|
2019-05-06 |
2022-01-05 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
|
|
WO2020232119A1
(en)
*
|
2019-05-14 |
2020-11-19 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2021007146A1
(en)
|
2019-07-07 |
2021-01-14 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
JP2022543832A
(ja)
|
2019-08-06 |
2022-10-14 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
変異体を治療するためのエストロゲン受容体調節剤
|
|
JP2022553833A
(ja)
*
|
2019-11-04 |
2022-12-26 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
エストロゲン受容体調節薬の塩及び形態
|
|
US11952349B2
(en)
|
2019-11-13 |
2024-04-09 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20220119415A
(ko)
|
2019-12-20 |
2022-08-29 |
씨4 테라퓨틱스, 인코포레이티드 |
Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
|
|
US12428428B2
(en)
|
2020-01-10 |
2025-09-30 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
|
|
CA3165309A1
(en)
|
2020-03-05 |
2021-09-10 |
Christopher G. Nasveschuk |
Compounds for targeted degradation of brd9
|
|
WO2021178846A1
(en)
|
2020-03-06 |
2021-09-10 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
MX2022013258A
(es)
|
2020-04-24 |
2022-11-14 |
Astrazeneca Ab |
Formulaciones farmaceuticas.
|
|
WO2021214253A1
(en)
|
2020-04-24 |
2021-10-28 |
Astrazeneca Ab |
Dosage regimen for the treatment of cancer
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
CA3188313A1
(en)
|
2020-08-05 |
2022-02-10 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of ret
|
|
WO2022029799A1
(en)
*
|
2020-08-05 |
2022-02-10 |
Aizant Drug Research Solutions Private Limited |
Solid dosage forms of palbociclib
|
|
WO2022109395A2
(en)
|
2020-11-23 |
2022-05-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
JP2024502270A
(ja)
|
2020-12-23 |
2024-01-18 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
エストロゲン受容体調節薬
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
IL308104A
(en)
|
2021-05-03 |
2023-12-01 |
Nuvation Bio Inc |
Nuclear hormone receptor-targeted compounds against cancer
|
|
CN117940133A
(zh)
|
2021-06-08 |
2024-04-26 |
C4医药公司 |
用于突变braf的降解的治疗剂
|
|
CA3226156A1
(en)
*
|
2021-07-08 |
2023-01-12 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
TW202317582A
(zh)
|
2021-07-09 |
2023-05-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
三環四氫異喹啉類衍生物的鹽型
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
JP2025525917A
(ja)
|
2022-08-03 |
2025-08-07 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｒｅｔタンパク質を調節するための化合物
|
|
CN120569388A
(zh)
|
2022-11-04 |
2025-08-29 |
百时美施贵宝公司 |
Ret-ldd蛋白降解剂
|
|
EP4611900A1
(en)
|
2022-11-04 |
2025-09-10 |
Bristol-Myers Squibb Company |
Ret-ldd protein inhibitors
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|